Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.43 |
| ▸ | PDE4A | P27815 | 8/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508512 | 0.85 | KCNA3 (0.43) | PDE4DBRD4KCNA3 | |
| SCHEMBL509081 | 0.82 | PDE4D (0.47) | PDE4DPDE4A | |
| SCHEMBL509371 | 0.80 | PDE4D (0.68) | PDE4D | |
| SCHEMBL510059 | 0.76 | PDE4A (0.59) | PDE4DPDE4A | |
| SCHEMBL509745 | 0.74 | SMPD3 (0.36) | PDE4DBRD4 | |
| SCHEMBL508221 | 0.71 | PDE4D (0.59) | PDE4DPDE4A | |
| SCHEMBL17571398 | 0.71 | PDE4D (0.48) | PDE4DPDE4A | |
| SCHEMBL509401 | 0.71 | PDE4A (0.64) | PDE4DPDE4A | |
| SCHEMBL509400 | 0.70 | PDE4A (0.61) | PDE4DPDE4A | |
| SCHEMBL3469402 | 0.70 | PDE4A (0.58) | PDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379548-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-8952162-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2015-02-10 | — | — | US | disclosed |
| US-20120028974-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2012-02-02 | — | — | US | disclosed |
| EP-2379548-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010069322-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028974-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE4A, PDE4B, PDE5A | PDE4D 5/4885PDE4A 1/4885BRD4 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.